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Background: Pseudo (platelet-type)-von Willebrand disease is a rare autosomal dominant bleeding disorder caused
by an abnormal function of the glycoprotein lb protein; the receptor for von Willebrand factor. This leads to an
increased removal of VWF multimers from the circulation as well as platelets and this results in a bleeding diathesis.
Worldwide, less than 50 patients are reported with platelet type von Willebrand disease (PT-VWD).
Case presentation: We describe the management of platelet type von Willebrand disease in pregnancy of a 26
year old Caucasian primigravida. The initial diagnosis was made earlier following a significant haemorrhage post
tonsillectomy several years prior to pregnancy. The patient was managed under a multidisciplinary team which
included obstetricians, haematologists, anaesthetists and neonatologists. Care plans were made for the ante- natal,
intra-partum and post-partum periods in partnership with the patient. The patient’s platelet count levels dropped
significantly during the antenatal period. This necessitated the active exclusion of other causes of thrombocytopenia in
pregnancy. A vaginal delivery was desired and plans were made for induction of labour at 38 weeks of gestation with
platelet cover in view of the progressive fall of the platelet count. The patient however went into spontaneous labour
on the day of induction. She was transfused two units of platelets before delivery. She had an unassisted vaginal
delivery of a healthy baby. The successful antenatal counselling has encouraged the diagnosis of the same condition in
her mother and sister. We found this to be a particularly interesting case as well as challenging to manage due to its
rarity. Psuedo von Willebrand disease in pregnancy can be confused with a number of other differential diagnoses,
such as gestational thrombocutopenia, idiopathatic thrombocytopenia, thrombotic thrombocytopenic purpura and
pre-eclampsia; all need consideration during investigations even in a case such as this where the diagnosis of platelet
type von Willebrand disease was known before pregnancy.
Conclusion: Management of pseudo von Willebrand disease in pregnancy involves the co-operation of
multidisciplinary teams, regular monitoring of platelet levels and factor VIII and replacement as appropriate. This case
report highlights this rare condition and the need to exclude all the other differential diagnoses of thrombocytopenia
in pregnant women with thrombocytopenia.
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Von Willebrand disease (VWD) is the most common her-
editary coagulopathy which results from the deficiency or
abnormal function of von Willebrand factor (VWF) which
is required for platelet adhesion and aggregation. VWF
produced in the endothelium is a multimeric glycoprotein
which assists in platelet plug formation by attracting* Correspondence: vboama@yahoo.co.uk
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reproduction in any medium, provided the orcirculating platelets to the site of damage and binds to
Factor VIII preventing its clearance from plasma. Presen-
tation varies according to the extent of deficiency and
ranges from abnormal menstrual bleeding, bleeding from
gums, and nosebleeds to haemathrosis.
The three hereditary types of VWD described are type
1, type 2 and type 3. Type 1 is a quantitative defect and
type 2 is a qualitative defect. The severest form is type 3
which is a quantitative defect in which levels of VWF mul-
timers may be undetectable. Type 2B von Willebrand dis-
ease was first described in 1980 and is caused by aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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an autosomal dominant bleeding disorder and results
from a gain of mutation in the VWF gene, commonly
exon 28 coding for the A1 domain.
Closely similar to type 2B is the platelet-type or pseudo-
von Willebrand disease (PT-VWD). It is an autosomal
dominant disorder caused by gain of function mutations
of the VWF receptor on platelets. There is an abnormally
enhanced binding of normal VWF to an abnormal platelet
glycoprotein Iba (GP1ba) receptor [1].
Mutation in the GP Iba gene (GP1BA) on chromosome
17 results in impairment of the haemostatic function of
VWF due to accelerated removal of VWF multimers from
the circulation [2].
The Phenotype of PT-VWD is as a result of 4 reported
mutations [3-6]:
1) Gly233Val mutation.
2) Met239Val mutation. This plays a critical role in
regulation of VWF binding,
3) Gly233Ser mutation,
4) 27 base pair deletion.
Patients with PT-VWD and type 2b VWD have simi-
lar phenotypic parameters and clinical symptoms and
distinguishing between the two can be a diagnostic
challenge. However, these two conditions have differ-
ent aetiology and require different treatment modal-
ities [7]. A recent case series of platelet type von
Willebrand disease in pregnancy highlights the rarity
and importance of this condition [8]. The diagnostic
criteria for PT-VWD can be challenging and current
scientific literatures still debate it. An International
registry –based study [9] has reported less than 50
patients worldwide with PT-VWD. This important
study also provides the frequency of PT-VWD versus
type 2B VWD in addition to the percentage of misdiag-
nosis of PT-VWD. A clear diagnostic criterion is
explained in this publication.
Differentiation of the two conditions has important
therapeutic implications. Whereas some patients with
type2B VWD can be treated with desmopressin, this is
generally avoided as it causes release of abnormal VWF
and worsens the bleeding condition. Ideally, patients
are treated with platelet transfusion however the major-
ity require treatment with a plasma –derived VWF/fac-
tor VIII concentrates and cryoprecipitate. The use of
cryoprecipitate in PT- VWD remains contentious, with
increasing thrombocytopenia having been reported
with these products .Partial correction of plasma VWF
level however has been effective in some patients as
reviewed by Miller [2]. An individualised approach is
suggested for both treatment and prophylaxis in PT-
VWD.Case presentation
A 26 year old primigravida was referred to the antenatal
clinic at 14 weeks gestation with a known diagnosis of
pseudo (platelet type) von Willebrand disease. The pa-
tient had been asymptomatic with this condition until
diagnosis at the age of 16 following excessive haemor-
rhage immediately after a tonsillectomy. Haematology
clinical records indicate the following results at the ini-
tial diagnosis: type of GP1BA mutation as Gly233Val,
VWF:Ag as 54 IU/dL, VWF:RCO as 38 IU/dL and Fac-
tor VIII as 68 IU/dL. The results of VWF levels could
not be found and hence are not included. At the time of
her antenatal booking, she was asymptomatic and was
not undergoing any treatment for her condition. A truly
multi-disciplinary team (MDT) was involved in her ante-
natal, intra-partum and postpartum care which included
haematologists, anaesthetists, neonatologists as well as
senior obstetricians.
Antenatal care
The antenatal plan was discussed with the patient during
several visits and the MDT. A plan was made for vaginal
delivery at term. To facilitate a safe pregnancy and deliv-
ery, the following care plan was made:
• Regular antenatal follow up at 24, 28, 32 and 36
weeks gestation
• FVIII and platelet levels to be checked at 24 and 32
weeks gestation
• HLA-matched platelets to be made available on site
for delivery
• Any admission associated with the risk of bleeding
should prompt a request for the appropriate platelets
Intra-partum care plan
• Traumatic delivery should be avoided as the baby has
a 50% chance of inheriting the bleeding disorder.
• Regional anaesthesia absolutely contraindicated
Post-partum care plan
• Umbilical cord blood for platelet count as well as
VWF of the new born
Routine dating scan was performed by a sonographer at
12 weeks gestation. A fetal anomaly scan was performed
at 20 weeks gestation. No abnormality of the fetus or pel-
vic and genital structures was identified. No placental ab-
normalities were noted. Serial fetal growth scans at 28, 32
and 36 weeks indicated a normal growing fetus.
Throughout the pregnancy the patient became in-
creasingly thrombocytopenic, but remained asymptom-
atic and clinically well. Other causes of thrombocytopenia
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bocytopenia and thrombotic thrombocytopenia were
considered and investigated in order to exclude their
superimposition on PT-VWD. The following investiga-
tions were performed to exclude the above differential
diagnosis: a full blood count, clotting screen, a blood film,
serum urea, creatinine and electrolytes, 24 hour urine pro-
tein collection, liver function tests, regular blood pressure
monitoring and a full clinical and neurological examina-
tions. The results of all these investigations remained nor-
mal throughout the pregnancy with the exception of the
platelet count levels. At 32 weeks the worsening throm-
bocytopenia (Table 1) prompted a change in the delivery
plan. Discussion between the MDT and patient led to the
following new plan:
• Induction of labour at 38 weeks in view of worsening
thrombocytopenia.
• Cross match 4 units of blood on admission at the
time of induction of labour .
• Weekly platelet count until the time of delivery.
The patient was admitted at 38 weeks gestation for in-
duction of labour. She however went into spontaneous
labour on the day of her induction. She required 2 units
of platelet transfusion before delivery. The active stage of
labour lasted about 8 hours. She had an unassisted vaginal
delivery of a healthy male baby weighing 3.15 kg with an
Apgar score of 9 in 1 minute and 10 in 5 minutes. The
total blood loss at delivery was 400ml. The paediatricians
attending the delivery performed a comprehensive review
of the neonate and also performed the cord blood tests
for platelet count and VWF levels. We were informed by
the paediatric team that the cord blood tests were all
within the normal range.
Postnatal
The post- partum period was uneventful and she remained
clinically well and asymptomatic. Her platelet count wasTable 1 Blood results





Booking 13.6 171 4.55 0.4
24 weeks 12.6 62 3.93 0.3
28 weeks 13.1 38 4.07 0.3
32 weeks 12.6 17 3.89 0.3
34 weeks 12.5 35 3.93 0.3
36 weeks 13.0 23 4.11 0.3
37 weeks 13.5 40 4.21 0.3
38 weeks 12.9 19 4.05 0.3
Day 1 postpartum 11.1 49 3.47 0.349 on day 1 postpartum. She was followed up in the com-
munity by her general practitioner ( GP) and the haema-
tology team. Her platelet count was 81 and 175 at 2 weeks
and 6 weeks postpartum respectively. The patient and her
family continue to be under the care of the GP and the
haematology team.
Conclusions
In our patient, there was no diagnostic challenge in dis-
tinguishing it from type 2B VWD since the diagnosis of
platelet type von Willebrand disease (PT-VWD) had
been established pre-pregnancy. Bone marrow biopsy
was not performed as we did not find it an appropriate
investigation under the circumstances. Von Willebrand
factor during the pregnancy were not checked since it
was felt by the team that it was not going to affect the
clinical management. The challenges faced in this case
were determining when to institute platelet transfusion
and whether to give cryoprecipitate and also when
to induce labour in view of the significant drop in
platelet count with advancing gestation. There were
also concerns about the wider differential diagnosis of
thrombocytopenia including superimposed preeclamp-
sia, gestational thrombocytopenia, idiopathic throm-
bocytopenia and thrombotic thrombocytopenia which
were actively excluded. The rarity of this condition and
hence the relative lack of expertise in its management
made it more challenging. The involvement of multi-
disciplinary senior team members resulted in a success-
ful outcome for both the patient and the neonate. The
opportunistic counselling that this patient received
during her pregnancy also led to the diagnosis under
the haematologist of the same condition in both her
mother and sibling.
This rare case may have educational value to many obste-
tricians and haematologists worldwide because it highlights
the haemostatic complications with pregnancy. We recom-
mend including PT-VWD in the investigation list for every
pregnant woman who presents with thrombocytopenia forT MCV MCH Prothrombin
time (S)
APTT (S) Factor VIII (%)
34 88.3 29.9
5 89.7 32.0 101
7 92.3 32.3
58 91.2 32.4 13 26 183
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that Platelet type von Willebrand disease may be found to
be more common than current literature indicates if it is
sufficiently investigated.
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